Clareo Health | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com
During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen
During cohort expansion, subjects with advanced cancer that either have received at least one prior therapy or are treatment naive, depending on the specified tumor type
Subjects must have measurable disease
Subject must consent to provide previously collected tumor tissue and a tumor biopsy during screening.
At least 4 weeks since any previous treatment for cancer
Must be able to swallow pills or capsules
Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1
You may not be if
Active or chronic autoimmune diseases
Uncontrolled or significant cardiovascular disease
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma)
Active central nervous system (CNS) metastases and CNS metastases as the only sites of disease
